Articles

Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia

Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Deo. of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada;
Haematologica Early view Jan 2, 2020 https://doi.org/10.3324/haematol.2019.235721